The rapid expansion of cellular therapies has created a pressing need for practical guidance on selecting, designing, and qualifying the manufacturing process for cellular products and in-process testing equipment. Unlike traditional biopharmaceuticals, cellular products pose distinct challenges in aseptic processing, automation, scalability, and technology selection, and scalability. This Guide addresses these challenges by offering expert analysis, actionable recommendations, and real-world insights into current and emerging technologies. It focuses on equipment used in the GMP manufacture of autologous and allogeneic therapies, including gene-modified and unmodified cell products. Engineered tissues, in vivo gene therapies, and exosome products are not covered due to their unique requirements. The Guide defines equipment applicability, functional ranges, and opportunities to reduce manual steps through automation and digital tools. It presents broad best practices on better understood topics, with detailed technical guidance on specific equipment types. Aligned with international regulatory frameworks and industry guidance—including FDA, EMA, PIC/S, and ISPE Baseline® Guides—it supports manufacturers evaluating new equipment and vendors developing solutions for the cell therapy sector. Developed by ISPE’s ATMP Community of Practice, this Guide aims to advance industry practices and foster innovation in closed, automated, scalable, and cost-effective cell therapy manufacturing systems. A list of regulatory and industry guidance references for ATMPs is included in the E-Reader (under Materials/Supplements) as a downloadable Microsoft® Word® file to purchasers of the Guide. See the FAQ for access instructions. The first of its kind, this reference list provides a comprehensive index of regulatory, international organizations, and industry guidance covering the ATMPs in clinical, GMP, and hospital environments.